Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25364915 | 0.83 | HRH3 (0.41) | PIK3CDJAK3PTK2PTGS2 | |
| SCHEMBL30557367 | 0.83 | HRH3 (0.41) | PIK3CDJAK3PTK2PTGS2 | |
| SCHEMBL25365711 | 0.82 | PIK3CD (0.38) | PIK3CDJAK3PTK2TLR8TLR7 | |
| SCHEMBL24266225 | 0.81 | PLAT (0.42) | PLATPIK3CDJAK3PTK2FAAH | |
| SCHEMBL25366803 | 0.81 | TLR9 (0.40) | PIK3CDJAK3PTK2TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL29399172 | 0.80 | PLAT (0.42) | PLATPIK3CDJAK3PTK2FAAH | |
| Hydrochloric Acid SCHEMBL25414817 | 0.80 | PLAT (0.42) | PLATPIK3CDJAK3PTK2FAAH | |
| SCHEMBL25367084 | 0.80 | GPR119 (0.55) | JAK3PTK2FAAH | |
| SCHEMBL25364620 | 0.80 | PIK3CD (0.38) | PIK3CDJAK3PTK2TLR8TLR7 | |
| SCHEMBL30557426 | 0.80 | PIK3CD (0.38) | PIK3CDJAK3PTK2TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4479135-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159154-A9 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023159154-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | PLAT 3883/4885PIK3CD 1217/4885JAK3 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.